Biophytis S.A. (ALBPS.PA)
EUR 0.29
(-2.24%)
EUR 0.29
(-2.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -803 Thousand EUR | -65.91% |
| 2022 | -484 Thousand EUR | -55.63% |
| 2021 | -311 Thousand EUR | -11.07% |
| 2020 | -280 Thousand EUR | -6.87% |
| 2019 | -262 Thousand EUR | -15.42% |
| 2018 | -227 Thousand EUR | -11.27% |
| 2017 | -204 Thousand EUR | -22.16% |
| 2016 | -167 Thousand EUR | -156.92% |
| 2015 | -65 Thousand EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - EUR | 0.0% |
| 2024 Q1 | - EUR | 100.0% |
| 2023 Q2 | -150 Thousand EUR | 0.0% |
| 2023 Q3 | - EUR | 100.0% |
| 2023 FY | -803 Thousand EUR | -65.91% |
| 2023 Q4 | -653 Thousand EUR | 0.0% |
| 2023 Q1 | - EUR | 100.0% |
| 2022 Q2 | -150 Thousand EUR | 0.0% |
| 2022 Q1 | - EUR | 100.0% |
| 2022 FY | -484 Thousand EUR | -55.63% |
| 2022 Q3 | - EUR | 100.0% |
| 2022 Q4 | -334 Thousand EUR | 0.0% |
| 2021 Q4 | -181 Thousand EUR | 0.0% |
| 2021 FY | -311 Thousand EUR | -11.07% |
| 2021 Q1 | - EUR | 100.0% |
| 2021 Q2 | -130 Thousand EUR | 0.0% |
| 2021 Q3 | - EUR | 100.0% |
| 2020 Q4 | -146 Thousand EUR | 0.0% |
| 2020 Q1 | - EUR | 100.0% |
| 2020 Q3 | - EUR | 100.0% |
| 2020 Q2 | -134 Thousand EUR | 0.0% |
| 2020 FY | -280 Thousand EUR | -6.87% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | -262 Thousand EUR | -15.42% |
| 2019 Q4 | -134 Thousand EUR | 0.0% |
| 2019 Q3 | - EUR | 100.0% |
| 2019 Q2 | -128 Thousand EUR | 0.0% |
| 2018 Q3 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2018 FY | -227 Thousand EUR | -11.27% |
| 2018 Q4 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 FY | -204 Thousand EUR | -22.16% |
| 2017 Q1 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 FY | -167 Thousand EUR | -156.92% |
| 2016 Q2 | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 FY | -65 Thousand EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 229.935% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 120.516% |
| Adocia SA | 1.38 Million EUR | 157.978% |
| Aelis Farma SA | 12.35 Million EUR | 106.498% |
| Advicenne S.A. | 1.42 Million EUR | 156.311% |
| genOway Société anonyme | 20.1 Million EUR | 103.995% |
| IntegraGen SA | 5.01 Million EUR | 116.001% |
| Medesis Pharma S.A. | -2.66 Million EUR | 69.866% |
| Neovacs S.A. | 29.31 Thousand EUR | 2839.305% |
| NFL Biosciences SA | -56.06 Thousand EUR | -1332.292% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 137.298% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 43.422% |
| Sensorion SA | 3.78 Million EUR | 121.199% |
| Theranexus Société Anonyme | -4.63 Million EUR | 82.689% |
| TME Pharma N.V. | -127 Thousand EUR | -532.283% |
| Valbiotis SA | 2.66 Million EUR | 130.097% |
| TheraVet SA | -530.79 Thousand EUR | -51.282% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 163.378% |
| argenx SE | 925.49 Million EUR | 100.087% |
| BioSenic S.A. | 543 Thousand EUR | 247.882% |
| Celyad Oncology SA | 33 Thousand EUR | 2533.333% |
| DBV Technologies S.A. | 4.15 Million EUR | 119.305% |
| Galapagos NV | 203.73 Million EUR | 100.394% |
| Genfit S.A. | 28.22 Million EUR | 102.845% |
| GeNeuro SA | -293.8 Thousand EUR | -173.315% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 140.271% |
| Innate Pharma S.A. | -4.12 Million EUR | 80.514% |
| Inventiva S.A. | 17.5 Million EUR | 104.589% |
| MaaT Pharma SA | 1.65 Million EUR | 148.52% |
| MedinCell S.A. | 9.28 Million EUR | 108.646% |
| Nanobiotix S.A. | 36.2 Million EUR | 102.218% |
| Onward Medical N.V. | -14.81 Million EUR | 94.581% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 105.757% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 136.057% |
| Oxurion NV | 104 Thousand EUR | 872.115% |
| Pharming Group N.V. | 220.1 Million EUR | 100.365% |
| Poxel S.A. | 1000.00 EUR | 80400.0% |
| GenSight Biologics S.A. | 3 Million EUR | 126.767% |
| Transgene SA | -28.4 Million EUR | 97.173% |
| Financière de Tubize SA | -2.02 Million EUR | 60.435% |
| UCB SA | 3.34 Billion EUR | 100.024% |
| Valneva SE | 52.83 Million EUR | 101.52% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 74.055% |